Scorpion antivenom nanobody production in Escherichia coli (Recombinant bispecific VHH)

Scorpionism is a serious public health problem in tropical areas, especially in Africa, southern India, the Middle East, and Latin America. There are about 12 species of scorpions that are dangerous to humans and all belong to the Buthidae family. In particular, venom on scorpion Androctonus australis hector is particularly toxic to humans. Serotherapy uses antibodies or fragments of antibodies to target the neurotoxins of the scorpion venom. Nanobodies, camelid-derived antibodies, are more effective than the conventional fragments of antibodies due to their low molecular weight (15 kDa). The Laboratoire des Venins et Molécules Thérapeutiques of the Pasteur Institute of Tunis (LVMT-IPT, Tunis, Tunisia) has produced promising bispecific nanobodies against the neurotoxins of the Androctonus australis hector scorpion. The production of the recombinant nanobodies NbF12-10 and CH10-12 in Escherichia coli was studied to determine the optimal conditions for their production at bioreactor scale.

Programme: Bioindustry 4.0

SEEK ID: https://ibisbahub.eu/projects/88

Public web page: Not specified

Organisms: Escherichia coli

IBISBA PALs: No PALs for this Project

Project start date: 6th Feb 2017

Powered by
(v.1.17.1)
Copyright © 2008 - 2025 The University of Manchester and HITS gGmbH
IBISBA is a pan-European research infrastructure currently funded through multiple EU projects: IBISBA 1.0 (H2020 grant agreement No. 730976), PREP-IBISBA (H2020 grant agreement No. 871118) and the follow-on project IBISBA-DIALS (grant agreement No. 101131085) and BIOINDUSTRY 4.0 (Grant agreement No. 101094287). Registering data or other knowledge assets on this platform is the sole responsibility of Users. IBISBA cannot be held responsible for misuse or misappropriation of data and assets belonging to a Third Party.